The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and ...

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...